All children were treated with antibiotics according to WHO classification and treatment of childhood pneumonia at health facilities 2012 [18], at enrollment after obtaining consent from parents and completing the baseline assessment, children were given a single injection of one ml of 100.000 IU of vitamin D3 (Cholecalciferol), vitamin D3 obtained from 2 ml vials containing 200,000 IU each (Devarol- S- 200.000 I.U. produced by Memphis for Pharmaceutical and Chemical Industries) and stored in manufacturer's recommended conditions in a dry, cool environment for 1-16 weeks (depending on the date of recruitment) . Syringes were labeled with a unique ID number and given by the blinded doctors choosing the next syringe with a randomization code.

All children were treated with antibiotics according to WHO classification and treatment of childhood pneumonia at health facilities 2012 [18], at enrollment after obtaining consent from parents and completing the baseline assessment, children were given a single injection of one ml saline injection. Syringes were labeled with a unique ID number and given by the blinded doctors choosing the next syringe with a randomization code.

Child, Hospitalized

Vitamin D Deficiency

Pneumonia

All children were treated with antibiotics according to WHO classification and treatment of childhood pneumonia at health facilities 2012 [18], at enrollment after obtaining consent from parents and completing the baseline assessment, children were given a single injection of one ml of 100.000 IU of vitamin D3 (Cholecalciferol), vitamin D3 obtained from 2 ml vials containing 200,000 IU each (Devarol- S- 200.000 I.U. produced by Memphis for Pharmaceutical and Chemical Industries) and stored in manufacturer's recommended conditions in a dry, cool environment for 1-16 weeks (depending on the date of recruitment) or placebo which is 1 ml saline injection. Syringes were labeled with a unique ID number and given by the blinded doctors choosing the next syringe with a randomization code. (only office secretary aware of randomization codes).

A single one ml injection

Faculty of Medicine, Cairo University

Effect of Vitamin D Supplementation on Improvement of Pneumonic Children

Randomized Controlled Trial of Vitamin D Supplementation on Improvement of Pneumonic Children at Tertiary Pediatric Hospital in Egypt

Patients' percent change of Vitamin D (25 (OH)D) will be calculated to quantify the change levels before and after vitamin D3 (Cholecalciferol) administration through the equation:
Pediatric, Blood Vitamin D level (BVD) %change = [(BVD after - BVD before) ÷ BVD before] × 100

Shaimaa Ali Mohamed Abd El Fatah

Assistant Professor

Cairo University

Fever of Unknown Origin

tuberclin test used to diagnose tuberculosis as cause of fever of unknown origin

tuberculin test

Causes of FUO in Infants and Children

Causes of Fever of Unknown Origin (FUO) in Infants and Children Attending Assiut University Children Hospital (AUCH)

Randa Mohammed Abd El Twab

Principal Investigator

Assiut University

Patients with a Tyrosinemia type 1 or high-grade suspi-cion for Tyrosinemia type 1

For the development of the new biomarkers using the technique of Mass-spectrometry, a blood sample of maximal 7,5 ml blood will be taken from the patient via using a dry blood spot filter card. To proof the correct diagnosis a Tyrosinemia type 1, in those patients where up to the enrollment in the study no genetic testing has been done, sequencing of a Tyrosinemia type 1 will be done. The analyses will be done at: Centogene AG Am Strande 7 18055 Rostock Germany

Tyrosinosis

Hepatorenal Tyrosinemia

Fumarylacetoacetase Deficiency

Fah Deficiency

Metabolic Disorders

Centogene is one of the leading laboratories focusing on genetic testing for rare hereditary disorders. We now offer more than 2200 routine genetic and biochemical tests.

Centogene AG

NIRMAN Navi Mumbai Institute of Research In Mental And Neurological Handicap/Pediatric Geneticist

Lady Ridgeway Hospital for Children

Biomarker for the Early Diagnosis and Monitoring in Tyrosinemia Type 1 (BioTyrosin)

BioTyrosin - Biomarker for the Early Diagnosis and Monitoring in Tyrosinemia Type 1 - An International, Multicenter, Epidemiological Protocol

Next-Generation Sequencing (NGS) of the FAH gene will be performed. The mutation will be confirmed by Sanger sequencing.

The quantitative determination of small molecules (molecular weight 150-700 kD, given as ng/μl) within a dried blood spot sample will be validated via liquid chromatography multiple reaction-monitoring mass spectrometry (LC/MRM-MS) and compared with a merged control cohort. The statistically best validated molecule will be considered as a disease specific biomarker.

Centogene AG Rostock

Patients with Hypophosphatasia disease or high-grade suspicion for Hypophosphatasia disease

For the development of the new biomarkers using the technique of Mass-spectrometry 7, 5 ml EDTA blood and a dry blood spot filter card are taken. To proof the correct di- agnosis of Hypophosphatasia in those patients where up to the enrollment in the study no genetic testing has been done, sequencing of Hypophosphatasia disease will be done. The analyses will be done at the: Centogene AG Am Strande 7 18055 Rostock Germany

Defective Mineralization

Biomarker for Hypophosphatasia Disease (BioHypophos)

Biomarker for Hypophosphatasia Disease AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL

Next-Generation Sequencing (NGS) of the ALPL gene will be performed. The mutation will be confirmed by Sanger sequencing.

rickets/feber

Effect of Vitamin D Supplementation on Improvement of Pneumonic Children

Causes of FUO in Infants and Children

Biomarker for the Early Diagnosis and Monitoring in Tyrosinemia Type 1 (BioTyrosin)

Biomarker for Hypophosphatasia Disease (BioHypophos)

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen